TY - JOUR
T1 - Is donepezil effective for multiple sclerosis-related cognitive dysfunction?
T2 - A critically appraised topic
AU - O'Carroll, Cumara B.
AU - Woodruff, Bryan K.
AU - Locke, Dona E.
AU - Hoffman-Snyder, Charlene R.
AU - Wellik, Kay E.
AU - Thaera, Greg M.
AU - Demaerschalk, Bart M.
AU - Wingerchuk, Dean M.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/1
Y1 - 2012/1
N2 - Background: Cognitive dysfunction affects approximately half of the patients with multiple sclerosis (MS). Cholinesterase inhibitor drugs are approved to treat cognitive dysfunction associated with degenerative dementia. Objective: To critically assess current evidence regarding the efficacy of the cholinesterase inhibitor, donepezil in the treatment of MS-associated cognitive impairment. Methods: The objective was addressed through the development of a structured critically appraised topic. This included a clinical scenario, structured question, literature search strategy, critical appraisal, results, evidence summary, commentary, and bottom line conclusions. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the fields of behavioral neurology and MS. RESULTS:: A randomized control trial was selected for critical appraisal. This trial randomized MS patients to receive donepezil 10 mg daily or placebo for treatment of MS-related cognitive dysfunction. There was no significant treatment effect found between the 2 groups on either the primary outcome of memory or any of the secondary cognitive measures. Post hoc analyses suggested a trend favoring donepezil in subjects with greater baseline cognitive dysfunction. Conclusions: Donepezil 10 mg daily for 24 weeks is not superior to placebo in improving MS-related cognitive dysfunction.
AB - Background: Cognitive dysfunction affects approximately half of the patients with multiple sclerosis (MS). Cholinesterase inhibitor drugs are approved to treat cognitive dysfunction associated with degenerative dementia. Objective: To critically assess current evidence regarding the efficacy of the cholinesterase inhibitor, donepezil in the treatment of MS-associated cognitive impairment. Methods: The objective was addressed through the development of a structured critically appraised topic. This included a clinical scenario, structured question, literature search strategy, critical appraisal, results, evidence summary, commentary, and bottom line conclusions. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the fields of behavioral neurology and MS. RESULTS:: A randomized control trial was selected for critical appraisal. This trial randomized MS patients to receive donepezil 10 mg daily or placebo for treatment of MS-related cognitive dysfunction. There was no significant treatment effect found between the 2 groups on either the primary outcome of memory or any of the secondary cognitive measures. Post hoc analyses suggested a trend favoring donepezil in subjects with greater baseline cognitive dysfunction. Conclusions: Donepezil 10 mg daily for 24 weeks is not superior to placebo in improving MS-related cognitive dysfunction.
KW - Multiple sclerosis
KW - cholinesterase inhibitors
KW - critically appraised topic
KW - evidence-based medicine
KW - memory disorders
UR - http://www.scopus.com/inward/record.url?scp=84855449213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855449213&partnerID=8YFLogxK
U2 - 10.1097/NRL.0b013e31823fa3ba
DO - 10.1097/NRL.0b013e31823fa3ba
M3 - Article
C2 - 22217618
AN - SCOPUS:84855449213
SN - 1074-7931
VL - 18
SP - 51
EP - 54
JO - Neurologist
JF - Neurologist
IS - 1
ER -